Table 1.
Patients in the Dartmouth RA Cohort a
| Patient demographics ( N = 193) | Seronegative | Seropositive |
|---|---|---|
| Number of patients (%) |
30 (16%) |
163 (84%) |
| Average age, yr (range) |
55.6 (29 to 72) |
57.9 (19 to 92) |
| Females, n (%) |
24 (80%) |
115 (71%) |
| RA duration <2 yr |
10 (33%) |
41 (25%) |
| SE status, n |
14 |
116 |
| SE alleles = 0 |
7 |
22 |
| SE alleles = 1 |
7 |
56 |
| SE alleles = 2 |
0 |
38 |
| C4 status, n |
14 |
111 |
| C4 copies <4 |
9 |
30 |
| C4 copies ≥4 |
5 |
81 |
| Medication history, n |
|
|
| No DMARDs |
9 |
36 |
| Nonbiologic DMARDs |
10 |
54 |
| TNF inhibitors |
4 |
42 |
| Other biologics | 7b | 31c |
aC4, Complement 4; DMARD, Disease-modifying antirheumatic drug; RA, Rheumatoid arthritis; SE, Shared epitope; TNF, Tumor necrosis factor. bAbatacept (n = 1) and rituximab (n = 6). cAbatacept (n = 2), rituximab (n = 27), tocilizumab (n = 1) and tofacitinib (n = 1).